– Transaction valued at $250 million, with up to$14 million in future milestones – – BioCryst will focus on driving ORLADEYO sales in the U.S. while Neopharmed Gentili will lead commercialization across Europe – – Provides a significant and immediate improvement to BioCryst’s operating margin – RESEARCH TRIANGLE PARK, N.C., Oct. 01, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has successfully completed the previously announced sale of its European ORLADEYO ...